HCP0910
Drug250/50, BID for 2 weeks
NCT Number: NCT01521455
The purpose of this study is to prove that HCP0910 is therapeutically equivalent to Seretide 250 Diskus when repeatedly dosed to Asthmatic patients.
Looking for future studies?
Notify Me20 year–75 year
All sexes
Interventional
Phase 1
Soon Chun Hyang University Hospital Bucheon, Bucheon-si, Gyunggi -do, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
250/50, BID for 2 weeks
250/50, BID for 2 weeks
Time frame: day 14
Hanmi Pharmaceutical Company Limited
Industry
A Phase I, Randomized, Open, Multi-center, Cross Over Study to Evaluate the Therapeutic Equivalence of Repeated Dose of HCP0910 250/50 μg to SeretideTM 250 DiskusTM in Asthmatic Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01399411
Asthma, Autoimmune Diseases
Iowa City, Illinois, United States
View Trial DetailsNCT03105843
Asthma, Bronchial Diseases
Kingston, Ontario, Canada
View Trial DetailsNCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial DetailsNCT03453112
Asthma, Bronchial Diseases
Hefei, Anhui, China
View Trial Details